Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROLUNG INCNone · Entity 163890 | Director | May 08, 2018 | May 11, 2018 |
| USANA HEALTH SCIENCES INCUSNA · Entity 6114 | Director | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROLUNG INC
Report date May 08, 2018 · Filed May 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-05-08 | Direct | 8,904 |
Reported balance
After 2018-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-08 · Grant · Acquired 8,904 · Balance 8,904 F1: The options vest 1/3 on date of grant, 1/3 on June 30, 2018, and 1/3 on September 30, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 1/3 on date of grant, 1/3 on June 30, 2018, and 1/3 on September 30, 2018.
USANA HEALTH SCIENCES INC
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,445 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Exercise / conversion · Acquired 1,632 · Balance 11,445 F1: Each restricted stock unit represents a contingent right to receive one share of USNA common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,895 |
Reported balance
After 2026-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-23 · Exercise / conversion · Disposed 1,632 · Balance 4,895 F1: Each restricted stock unit represents a contingent right to receive one share of USNA common stock. F2: Restricted Stock Units vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of USNA common stock.
F2: Restricted Stock Units vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2017 Filed Oct 25, 2017 20:36 UTC | USANA HEALTH SCIENCES INC USNA · Entity 6114 | GrantDeferred Stock Unit · Derivative | 859 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-013429 · edgar.xml · derivative · entry 1 Nixon J Scott · CIK 0001709352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 859 Underlying: Common Stock · 859 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Stock Unit ("DSU") represents the issuer's obligation to transfer one share of common stock in accordance with the terms of the deferred stock unit agreement pursuant to which the DSU's were granted. F2 · derivative.exercise_date: Following termination of the undersigned's service on the issuer's Board of Directors, the issuer will distribute to the undersigned shares of common stock equal to the number of DSU's granted. F2 · derivative.expiration_date: Following termination of the undersigned's service on the issuer's Board of Directors, the issuer will distribute to the undersigned shares of common stock equal to the number of DSU's granted. Read SEC document |
| August 24, 2017 Filed Aug 29, 2017 17:55 UTC | PROLUNG INC [None] · Entity 163890 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001709352-17-000002 · primary_doc.xml · derivative · entry 2 Nixon J Scott · CIK 0001709352 · Director · Audit Committee Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-08-24 F1 · derivative.exercise_date: The option vests in four equal quarterly installments: September 30, 2017; December 31, 2017; March 31, 2018; and June 30, 2018. Read SEC document |
| August 24, 2017 Filed Aug 29, 2017 17:55 UTC | PROLUNG INC [None] · Entity 163890 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001709352-17-000002 · primary_doc.xml · derivative · entry 1 Nixon J Scott · CIK 0001709352 · Director · Audit Committee Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-08-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.